BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 27911230)

  • 1. Bromodomain inhibitors and cancer therapy: From structures to applications.
    Pérez-Salvia M; Esteller M
    Epigenetics; 2017 May; 12(5):323-339. PubMed ID: 27911230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromodomains: Structure, function and pharmacology of inhibition.
    Ferri E; Petosa C; McKenna CE
    Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic Targets and their Inhibitors in Cancer Therapy.
    Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
    Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological function and histone recognition of family IV bromodomain-containing proteins.
    Lloyd JT; Glass KC
    J Cell Physiol; 2018 Mar; 233(3):1877-1886. PubMed ID: 28500727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small Molecules Targeting the Specific Domains of Histone-Mark Readers in Cancer Therapy.
    Zhu H; Wei T; Cai Y; Jin J
    Molecules; 2020 Jan; 25(3):. PubMed ID: 32013155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The exploitation of FRET probes to track bromodomain/histone interactions in cells for bromodomain inhibitors.
    Sasaki K; Yoshida M
    Drug Discov Today Technol; 2016 Mar; 19():51-56. PubMed ID: 27769358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bromodomain biology and drug discovery.
    Zaware N; Zhou MM
    Nat Struct Mol Biol; 2019 Oct; 26(10):870-879. PubMed ID: 31582847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
    Ramadoss M; Mahadevan V
    Drug Discov Today; 2018 Jan; 23(1):76-89. PubMed ID: 28943305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.
    Morse MA; Balogh KK; Brendle SA; Campbell CA; Chen MX; Furze RC; Harada IL; Holyer ID; Kumar U; Lee K; Prinjha RK; Rüdiger M; Seal JT; Taylor S; Witherington J; Christensen ND
    Antiviral Res; 2018 Jun; 154():158-165. PubMed ID: 29653131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule inhibitors of bromodomain-acetyl-lysine interactions.
    Brand M; Measures AR; Wilson BG; Cortopassi WA; Alexander R; Höss M; Hewings DS; Rooney TP; Paton RS; Conway SJ
    ACS Chem Biol; 2015 Jan; 10(1):22-39. PubMed ID: 25549280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
    To KKW; Xing E; Larue RC; Li PK
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromodomains and their pharmacological inhibitors.
    Gallenkamp D; Gelato KA; Haendler B; Weinmann H
    ChemMedChem; 2014 Mar; 9(3):438-64. PubMed ID: 24497428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Bromodomain: A New Target in Emerging Epigenetic Medicine.
    Smith SG; Zhou MM
    ACS Chem Biol; 2016 Mar; 11(3):598-608. PubMed ID: 26596782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy.
    Biswas S; Rao CM
    Eur J Pharmacol; 2018 Oct; 837():8-24. PubMed ID: 30125562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting bromodomains: epigenetic readers of lysine acetylation.
    Filippakopoulos P; Knapp S
    Nat Rev Drug Discov; 2014 May; 13(5):337-56. PubMed ID: 24751816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Epigenetics in Cancer.
    Bennett RL; Licht JD
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():187-207. PubMed ID: 28992434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
    Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
    Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-Molecule Targeting of BET Proteins in Cancer.
    French CA
    Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.